NEWARK, Calif.--(BUSINESS WIRE)--Mar. 5, 2019--
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company
developing next-generation neuromodulators for use in treating aesthetic
and therapeutic conditions, today announced that the Company will
participate in two upcoming investor conferences.
President and Chief Executive Officer, Dan Browne, is scheduled to
present at the Cowen and Company 39th Annual Health Care
Conference in Boston, MA on Tuesday, March 12 at 9:20am ET.
Chief Financial Officer, Tobin Schilke, is scheduled to present at the
Barclays Global Healthcare Conference in Miami, FL on Wednesday, March
13 at 3:50pm ET.
Interested parties can access the live audio webcasts for both
conferences from the Investor Relations section of the company's website
The webcast replays will be available after the conclusion of the live
presentations for approximately 30 days.
About Revance Therapeutics, Inc.
Revance Therapeutics is an emerging Silicon Valley biotechnology leader
developing neuromodulators for the treatment of aesthetic and
therapeutic conditions. Revance uses a unique proprietary peptide
excipient technology to create novel, differentiated therapies. The
company’s lead compound, DaxibotulinumtoxinA for Injection (RT002), is
in clinical development for a broad range of aesthetic and therapeutic
indications, including glabellar lines, cervical dystonia, plantar
fasciitis, upper limb spasticity and chronic migraine. RT002 has the
potential to be the first long-acting neuromodulator. The company is
advancing a robust pipeline of injectable and topical formulations of
daxibotulinumtoxinA. More information on Revance may be found at www.revance.com.
"Revance Therapeutics" and the Revance logo are registered trademarks of
Revance Therapeutics, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190305005130/en/
Source: Revance Therapeutics, Inc.
Revance Therapeutics, Inc.:
John Grimaldi, 212-213-0006
Mariann Caprino, 917-242-1087
Nadine Tosk, 504-453-8344